At long last, it seems a drug has been found to treat Alzheimer's disease. Lecanemab has been shown in trials to slow the progress of early-stage Alzheimer's - scientists found that after 18 months, the drug slowed disease progression by 27% compared with patients taking a placebo.
Tokyo-based pharmaceutical Eisai, who has partnered with US biotech firm Biogen to develop lecanemab, reported the phase three clinical trial results. And dementia researchers have now hailed them as a major step forward in the treatment of Alzheimer's.
Professor John Hardy, group leader at the UK Dementia Research Institute (UKDRI) at University College London, says: "This trial is an important first step, and I truly believe it represents the beginning of the end."
